GLP-1 maintenance dosing: what the evidence actually says

What's this video probably claiming?

Based on the caption, @realdrbae is promoting the idea of a "maintenance program" for GLP-1 receptor agonists, describing it as smaller or less frequently taken doses after an initial weight loss phase. The implied pitch is that patients can sustain their results on a lower, cheaper, or easier-to-tolerate dose rather than discontinuing the medication entirely or staying on full therapeutic doses indefinitely. This is a popular concept in telehealth weight loss circles right now, and it's being used to keep patients enrolled in subscription programs. The framing here is clinical and reassuring, which is exactly why it needs scrutiny. The comment-baiting structure of the caption also suggests this is a lead-generation post, not a medical education one.

What does the science actually show?

The honest answer is that long-term maintenance dosing for GLP-1s is an area of active research, and the data we have is not particularly encouraging for the low-dose concept. The STEP 4 trial (Rubino et al., 2021, JAMA) is the most cited evidence here. Participants who continued semaglutide 2.4 mg weekly after an initial 20-week run-in maintained roughly 7.9% additional weight loss at 48 weeks, while those switched to placebo regained about two-thirds of their prior loss. The takeaway from STEP 4 is not that lower doses work for maintenance. It is that discontinuation causes regain, and the trial used the full therapeutic dose throughout. There is no large randomized controlled trial showing that a reduced semaglutide or tirzepatide dose preserves weight loss outcomes equivalently to the standard dose. The SURMOUNT-4 trial (Aronne et al., 2024, JAMA) showed similar regain patterns with tirzepatide withdrawal.

Where does the social media noise diverge from clinical reality?

The gap between the maintenance-dosing narrative online and actual clinical evidence is significant. Telehealth creators frequently imply that 0.25 mg or 0.5 mg semaglutide weekly, doses used only during titration in the STEP trials, can serve as long-term maintenance doses. There is no peer-reviewed trial supporting that claim for weight management. What the evidence does show is that GLP-1 medications treat obesity as a chronic condition, meaning the biology driving weight regain does not disappear at goal weight. The Wilding et al., 2022 analysis of post-STEP 1 follow-up showed participants regained an average of 11.6 percentage points of their body weight within 12 months of stopping semaglutide. Framing dose reduction as a clinical strategy without disclosing this evidence is not neutral. It is misleading by omission, and it potentially sets patients up for regain while keeping them paying for a program.

What should you actually know?

If you are on a GLP-1 medication and wondering about long-term dosing, here is the honest picture. Your prescriber should be making dose decisions based on your individual response, tolerability, and goals, not a platform's subscription model. Some patients do stabilize at lower doses during titration and maintain reasonable results, but this is individual variation, not validated maintenance protocol. The current FDA-approved maintenance doses for weight management are semaglutide 2.4 mg weekly (Wegovy) and tirzepatide 10 mg or 15 mg weekly (Zepbound), based on where the trials demonstrated efficacy. Any dose below those has not been studied for weight maintenance in adequately powered trials. If a telehealth provider is recommending a specific compounded dose as a maintenance strategy, ask them to show you the trial data. Spoiler: they will not be able to, because it does not exist yet.